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Introduction {#sec005}
============

Age-related macular degeneration (AMD) is the leading cause of severe vision loss and blindness worldwide, and the incidence in developed countries ranges from 9% to 25% at ages 65 to 75 years \[[@pone.0213624.ref001],[@pone.0213624.ref002]\]. The risk of developing advanced AMD lesions increases with age and is ten-fold greater in people over 85 years compared those 65 to 75 years old \[[@pone.0213624.ref003]\]. According to the severity of the disease, AMD is classified as early, intermediate, and advanced. The advanced form includes atrophic and/or neovascular conditions \[[@pone.0213624.ref004]\].

The development of AMD is influenced by lifestyle (smoking), dietary factors, drusen accumulation, and parainflammation. In addition, the incidence of patients with AMD is also affected by genetic components \[[@pone.0213624.ref005],[@pone.0213624.ref006]\]. Current data suggests that the rs243865 matrix metalloproteinase-2 (MMP-2) polymorphism within the 16q13-q21 chromosomal region is associated with an increased risk of developing AMD \[[@pone.0213624.ref007]--[@pone.0213624.ref012]\]. The rs243865 polymorphism is located in the promoter transcription region of the MMP-2 gene, and it consists of a C\>T change (-1306C\>T). This modifies the promoter activity of the MMP-2 gene, altering the Sp1-type promoter site \[[@pone.0213624.ref013]\]. The MMP-2 gene is crucial for the regulation of extracellular matrix components \[[@pone.0213624.ref014],[@pone.0213624.ref015]\], and extracellular matrix dysregulation could be associated with the development of AMD \[[@pone.0213624.ref005]\]. In the studies of allelic association with AMD, the rs243865 MMP-2 polymorphism has been especially analyzed because it modifies MMP-2 activity. Several groups have reported the association between the rs243865 MMP-2 polymorphism and the risk of AMD \[[@pone.0213624.ref007]--[@pone.0213624.ref012]\]. However, the results from previous studies have been inconclusive, partly because each study was underpowered due to inadequate sample sizes. We have chosen to analyze the rs243865 polymorphism for two main reasons: (1) it modifies the MMP-2 gene promoter activity and, thus, the extracellular matrix regulation, which may be linked to the development of AMD \[[@pone.0213624.ref005]\]; and (2) because to the best of our knowledge, the rs243865 MMP-2 polymorphism has not been included in any genome-wide association (GWAS) or meta-analysis studies for AMD. Thus, we conducted this meta-analysis based on the published literature to characterize more precisely the potential association between the rs243865 polymorphism and AMD.

Materials and methods {#sec006}
=====================

The current study conformed to the checklist for meta-analysis of genetic association studies specified for PLOS One approach ([S1 Table](#pone.0213624.s001){ref-type="supplementary-material"}) \[[@pone.0213624.ref016]\].

Search strategy and selection criteria {#sec007}
--------------------------------------

To identify eligible studies, we searched in the PubMed, Web of Science, Scopus, and Embase electronic databases. Potentially relevant articles were sought by using the search terms in combination as Medical Subject Headings (MeSH) terms and text words: "matrix metalloproteinase-2", "polymorphism", "rs243865", "-1306C\>T", "age-related macular degeneration", "AMD", "macular degeneration", and "maculopathy". We also scanned the reference lists of the retrieved publications to identify additional relevant articles ([S2 Table](#pone.0213624.s002){ref-type="supplementary-material"}).

The following inclusion criteria were used to identify published articles for our meta-analysis: (1) associations between the rs243865 MMP-2 polymorphism and AMD published in the last 18 years; (2) study populations included only individuals not related to one another; (3) sufficient genotype data were presented to allow calculation of the odds ratios (ORs); (4) each study clearly described the diagnosis of AMD, which was limited to the National Institute for Health and Care Excellence (NICE) Age-Related Maculopathy grading system or the International Classification and Grading system \[[@pone.0213624.ref017],[@pone.0213624.ref018]\]; (5) the sources of the cases and controls were identified; and (6) genotype distributions complied with the Hardy--Weinberg equilibrium (HWE). In addition, we excluded reviews and redundant studies. Only English-language articles were analysed.

Data extraction {#sec008}
---------------

To improve the reliability of our results, two investigators (ALP, MML) used a standardised form to independently extract data. Any divergences of opinion were resolved by consensus with the senior authors (RGS, JCP). Second and third literature searches were conducted but did not contribute additional studies for the analyses. Citations were first scanned at the title/abstract level. Shortlisted studies were then retrieved in full text.

From each study, the following information was extracted: the author´s name, year of publication, location, and ethnicity and demographic information (age and sex) of the study population. Allele and genotype frequencies were extracted or calculated. HWE was verified for each eligible study. The corresponding authors of the original studies were contacted if further data were needed.

Quality assessment {#sec009}
------------------

Study quality was ranked as high, moderate, or low (score categories 7--9, 4--6, 0--3, respectively) by the Newcastle-Ottawa Quality Assessment Scale (NOS) \[[@pone.0213624.ref019]\]. Two independent reviewers conducted the data extraction and quality assessment, and disagreements were resolved by discussion ([S3 Table](#pone.0213624.s003){ref-type="supplementary-material"}).

Statistical analyses {#sec010}
--------------------

The main meta-analysis compared the presence of the variant T allele of rs243865 MMP-2 polymorphism among AMD patients as cases versus healthy subjects as controls. If three or more studies were available, further meta-analyses were performed comparing: (1) the presence of CT+TT genotype of rs243865 MMP-2 polymorphism among AMD patients and healthy subjects; (2) the presence of CT+TT genotype of rs243865 MMP-2 polymorphism among AMD patients and healthy subjects by age; and (3) the presence of CT+TT genotype of rs243865 MMP-2 polymorphism among AMD patients \> 65 years old and AMD patients \< 65 years old.

For each study, we used a random-effects model \[[@pone.0213624.ref020]\] to calculate the OR and the 95% confidence interval (CI) along with the respective p-values. P-values \< 0.05 were considered statistically significant. To evaluate heterogeneity, Cochran´s Q-statistic was used. For estimation of inconsistency in meta-analysis, the I^2^ statistic was determined, representing the percentage of the observed study variability attributed to heterogeneity rather than to chance \[[@pone.0213624.ref021]\]. Begger´s funnel plots were drawn to assess publication bias. Sensitivity analysis was performed by excluding individual studies. The meta-analysis was performed using RevMan 5.0 software \[[@pone.0213624.ref022]\]. Deviation of genotype frequencies from the HWE in healthy subjects was assessed by X^2^ test.

Results {#sec011}
=======

Characteristics of the included studies {#sec012}
---------------------------------------

A flow diagram of the study selection process is shown in [Fig 1](#pone.0213624.g001){ref-type="fig"}. The initial search identified 32 references for possible inclusion in our meta-analysis. After removing duplicates, 16 studies remained, and 10 of these were excluded after abstract examination revealed that they failed to meet the inclusion criteria ([S2 Table](#pone.0213624.s002){ref-type="supplementary-material"}). This step left 6 full articles that were assessed for eligibility \[[@pone.0213624.ref007]--[@pone.0213624.ref012]\], and none of them had to be removed. The corresponding author of three articles \[[@pone.0213624.ref009],[@pone.0213624.ref011],[@pone.0213624.ref012]\] was contacted due to doubts about a possible overlap of the patients and controls included in the articles. The corresponding author in each case confirmed to us that the patients and controls included in each article were different, so that the three articles were included in the meta-analysis. Therefore, a total of 6 studies were ultimately included ([Fig 1](#pone.0213624.g001){ref-type="fig"}). These studies included 1,682 AMD patients and 2,295 healthy subjects, and the population demographics are shown [Table 1](#pone.0213624.t001){ref-type="table"}.

10.1371/journal.pone.0213624.t001

###### Characteristics of the studies included in the meta-analysis.

![](pone.0213624.t001){#pone.0213624.t001g}

  Authors, year                Country     Ethnicity   Female/male ratio   Age, y \[mean ± SD or median (min---max)\]   HWE p-value                         
  ---------------------------- ----------- ----------- ------------------- -------------------------------------------- ----------------- ----------------- --------
  Cheng et al., 2017           China       Asian       42/84               50/91                                        62.4±9.6          63.8±10.2         0.117
  Liutkeviciene et al., 2016   Lithuania   Caucasian   186/201             330/352                                      65 (57--93)       66 (55--97)       0.664
  Ortak et al., 2013           Turkey      N/A         79/65               84/88                                        67.1 ± 6.9        66.1 ± 6.5        \>0.05
  Seitzman et al., 2008        USA         Caucasian   434/0               456/0                                        \> 60             \>60              \>0.05
  Liutkeviciene et al., 2017   Lithuania   Caucasian   164/126             316/210                                      67 (59.9--67.8)   68 (60.8--68.3)   0.528
  Liutkeviciene et al., 2018   Lithuania   Caucasian   168/99              205/113                                      75.4±7.6          74.7±8.4          0.382

AMD: Age-related macular degeneration; N/A: not available; y: years; SD: standard deviation; HEW: Hardy-Weinberg equilibrium.

![Flow chart of the selection of studies for inclusion in the meta-analysis.](pone.0213624.g001){#pone.0213624.g001}

Meta-analysis databases: Association between rs243865 MMP-2 polymorphism and AMD {#sec013}
--------------------------------------------------------------------------------

Each of the articles analysed in our meta-analysis included the genotypic and allelic frequencies of rs243865 MMP-2 polymorphism in AMD patients and healthy controls ([Table 2](#pone.0213624.t002){ref-type="table"}). All of the studies used genomic DNA extracted from nucleated peripheral blood cells, and genotyping was performed with polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP). There were no statistically significant deviations from the HWE in the control groups of any of the studies.

10.1371/journal.pone.0213624.t002

###### Genotype and allelic distribution of rs243865 MMP-2 polymorphism in age-related macular degeneration patients and healthy subjects.

![](pone.0213624.t002){#pone.0213624.t002g}

  Authors, year                Subject groups   N     Genotype distribution   Allele distribution                      
  ---------------------------- ---------------- ----- ----------------------- --------------------- ----- ------ ----- -----
  Cheng et al., 2017           AMD patients     126   94                      27                    5     32     215   37
  Healthy subjects             141              89    42                      10                    52    220    62    
  AMD patients \< 65 y         53               40    N/A                     N/A                   13    N/A    N/A   
  Healthy controls \< 65 y     76               49    N/A                     N/A                   27    N/A    N/A   
  AMD patients \> 65 y         73               54    N/A                     N/A                   19    N/A    N/A   
  Healthy controls \> 65 y     65               40    N/A                     N/A                   25    N/A    N/A   
  Liutkeviciene et al., 2016   AMD patients     387   229                     132                   26    158    590   184
  Healthy controls             682              385   252                     45                    297   1022   342   
  AMD patients \< 65 y         181              118   48                      15                    63    284    78    
  Healthy controls \< 65 y     306              186   103                     17                    120   475    137   
  AMD patients \> 65 y         206              111   84                      11                    95    306    106   
  Healthy controls \> 65 y     376              199   149                     28                    177   547    205   
  Ortak et al., 2013           AMD patients     144   80                      60                    4     64     220   68
  Healthy controls             172              108   64                      0                     64    280    64    
  Seitzman et al., 2008        ADM patients     434   N/A                     N/A                   N/A   N/A    660   208
  Healthy controls             456              N/A   N/A                     N/A                   N/A   678    234   
  Liutkeviciene et al., 2017   ADM patients     324   191                     112                   21    133    494   154
  Healthy controls             526              289   198                     39                    237   776    276   
  Liutkeviciene et al., 2018   AMD patients     267   157                     84                    26    110    398   136
  Healthy controls             318              190   108                     20                    128   488    148   
  AMD patients \< 65 y         99               56    35                      8                     43    147    51    
  Healthy controls \< 65 y     113              69    39                      5                     44    177    49    
  AMD patients \> 65 y         168              101   49                      18                    67    251    85    
  Healthy controls \> 65 y     205              121   69                      15                    84    311    99    

MMP-2, matrix metalloproteinase-2 gene; AMD, age-related macular degeneration; y, years of age; N/A, not available

After analysis of the pooled selected studies, there were no significant associations between the variant T allele ([Fig 2A](#pone.0213624.g002){ref-type="fig"}, p-value = 0.10, OR \[95%CI\] = 0.95 \[0.82--1.10\]) or the CT+TT genotype ([Fig 2B](#pone.0213624.g002){ref-type="fig"}, p-value = 0.16, OR \[95%CI\] = 0.92 \[0.76--1.12\]) of the rs243865 MMP-2 polymorphism and the presence of AMD ([Fig 2](#pone.0213624.g002){ref-type="fig"}). There were also no significant differences based on study population ethnicity. The sensitivity analysis, which excluded individual studies, did not modify these results. Further, there were no significant differences in the genotypic distribution of rs243865 MMP-2 polymorphism based on age between AMD patients and healthy subjects ([Table 3](#pone.0213624.t003){ref-type="table"}). Nor was there a difference in the genotypic distribution between AMD patients \> 65 years old and those \< 65 years old ([Table 3](#pone.0213624.t003){ref-type="table"}).

![Meta-analysis of the association between rs243865 MMP-2 polymorphism and age-related macular degeneration.\
(A) C vs. T allele. Test for overall effect: Z = 0.67 (P = 0.50). Test for heterogeneity: v2 = 9.17 (P = 0.10). Test for inconsistency: I^2^ = 46%. (B) CC vs. CT+TT genotype. Test for overall effect: Z = 0.82 (P = 0.41). Test for heterogeneity: v2 = 6.55 (P = 0.16), Test for inconsistency: I^2^ = 39%. Each study is shown by an OR estimate with the corresponding 95% CI.](pone.0213624.g002){#pone.0213624.g002}

10.1371/journal.pone.0213624.t003

###### Summary of meta-analysis results for the association of rs243865 MMP-2 polymorphism with age-related macular degeneration by age.

![](pone.0213624.t003){#pone.0213624.t003g}

                                                                 OR     95% CI       P (random-effects model)   I^2^   P (heterogeneity)
  -------------------------------------------------------------- ------ ------------ -------------------------- ------ -------------------
  **AMD patients \< 65 y vs healthy subjects \< 65 y (N = 3)**                                                         
  CC vs CT+TT                                                    0.88   0.66--1.17   0.44                       15%    0.31
  **AMD patients \> 65 y vs healthy subjects \> 65 y (N = 3)**                                                         
  CC vs CT+TT                                                    0.90   0.70--1.15   0.41                       0%     0.40
  **AMD patients \> 65 y vs AMD patients \< 65 y (N = 3)**                                                             
  CC vs CT+TT                                                    1.19   0.78--1.81   0.43                       44%    0.43

OR, odds ratio; CI, confidence interval; AMD, age-related macular degeneration; y, age in years; N, number of studies included in each meta-analysis.

Bias diagnostics {#sec014}
----------------

When there are fewer than 10 studies in a meta-analysis, the power of tests for funnel plot asymmetry is too low to distinguish chance from real asymmetry \[[@pone.0213624.ref023]\]. Even so, we examined publication bias by visual inspection using a Begger's funnel plot with the effect size, i.e., the OR, on the *x*-axis and the inverse of variance of the effect on the *y*-axis ([Fig 3](#pone.0213624.g003){ref-type="fig"}). The shape of the funnel plot for publication bias appeared to be symmetrical ([Fig 3A and 3B](#pone.0213624.g003){ref-type="fig"}), although there was some uncertainty regarding the degree of symmetry. Thus, the estimate of the effect was considered to be biased. Nevertheless, the results based on the Begger's test of the allele (C vs. T, [Fig 3A](#pone.0213624.g003){ref-type="fig"}) and the recessive (CC vs. CT/TT, [Fig 3B](#pone.0213624.g003){ref-type="fig"}) models showed no evidence of publication bias.

![Funnel plot of studies included in the meta-analysis assessing the association of the rs243865 MMP-2 polymorphism with age-related macular degeneration.\
The effect size (OR) was plotted on the x-axis, and the inverse of variance of the effect was plotted on the y-axis. (A) C vs. T allele. (B) CC vs. CT+TT genotype.](pone.0213624.g003){#pone.0213624.g003}

Sensitivity analyses {#sec015}
--------------------

Sensitivity analyses were performed after sequentially removing each eligible study. This approach is regarded as an indispensable step for analysing multiple criteria. The significance of the pooled ORs was not influenced by any single study in the recessive genetic model, indicating that our results were statistically robust.

Discussion {#sec016}
==========

The aetiology of AMD is unknown; nevertheless, several observations suggest that genetic alterations may be crucial in the development of the disease \[[@pone.0213624.ref005],[@pone.0213624.ref006]\]. To date, through GWAS, more than 50 independently associated common genetic variants distributed across more than 30 loci have been associated with a significantly increased susceptibility to developing AMD \[[@pone.0213624.ref024]--[@pone.0213624.ref026]\]. To our knowledge, none of them included an analysis of the rs243865 MMP-2 polymorphism. In particular, variations in the complement factor H gene and the ARMS2/HTRA1 genes have been considered to be the most consistent genetic risk factors for AMD development \[[@pone.0213624.ref027],[@pone.0213624.ref028]\]. The precise genetic factors, as well as their interactions, remain unclear in AMD. Therefore, in an attempt to prevent AMD, the identification of other potential genetic factors is crucial due to the lack of effective treatments at present.

AMD is characterised by drusen formation, which are accumulations of abnormal extracellular matrix deposits that cause visual function impairment \[[@pone.0213624.ref029],[@pone.0213624.ref030]\]. A growing number of studies suggest that the rs243865 MMP-2 polymorphism could be associated with increased susceptibility to AMD development \[[@pone.0213624.ref007]--[@pone.0213624.ref012]\]. However, the results from past studies remain inconclusive, with some studies supporting a significant association, while others claim the opposite. Also, caution should be undertaken when interpreting the results from these single studies as they are often underpowered due to inadequate sample sizes. The present meta-analysis, which incorporated 6 independent case-control studies, was designed to evaluate whether or not rs243865 MMP-2 polymorphism modifies the risk of developing AMD. In comparison to past single studies, our analysis included a large sample size, 1,682 AMD patients and 2,295 healthy subjects, with attendant increased statistical power. Also, a quality evaluation system was included to minimise the potential for bias. Based on this approach, our most significant finding was that the 16q13-q21 rs243865 MMP-2 polymorphism is not a risk factor for developing AMD.

MMPs and tissue regulators have a central role in the deposition of extracellular matrix accumulations in several diseases \[[@pone.0213624.ref031]--[@pone.0213624.ref034]\]. It has been reported that MMP-2, MMP-3, and MMP-9 could be related to the pathogenesis of AMD. MMP-2, also known as gelatinase A, participates in the degradation of extracellular matrix components like collagen and laminin \[[@pone.0213624.ref034]--[@pone.0213624.ref036]\]. The rs243865 MMP-2 variant is located in the promoter region of the gene, where it causes a modification in MMP-2 transcription due to the variant T allele alteration in the Sp1-type promoter site \[[@pone.0213624.ref013]\]. The C to T allelic variation disrupts the Sp1 binding site in the promoter region and leads to significantly lower transcriptional activity. Therefore, the T allele has a markedly lower activity (50%) than the C allele. Several authors have reported that the dysregulation of MMP-2 synthesis leads to the formation of deposits in the basement membrane of the retinal pigment epithelium that, in turn, could contribute to drusen formation, and therefore to AMD development \[[@pone.0213624.ref034]--[@pone.0213624.ref036]\]. Moreover, an increased amount of inactive MMP-2 has been found in the subretinal space of AMD patients compared to that in normal human donor eyes \[[@pone.0213624.ref037]\]. This diminished level of active MMP-2 could be related to a reduction in the remodelling and accumulation of basal laminar deposits in AMD subjects \[[@pone.0213624.ref038]\].

Although the MMP pathway could play an important role in AMD development, the results of our study suggest that the rs243865 MMP-2 polymorphism was not associated with an increased risk of developing AMD. In addition, no statistically significant differences were attributable to either ethnicity or age. Therefore, other genetic and/or environmental factors might be more crucial than the rs243865 MMP-2 polymorphism in the susceptibility of AMD development. In this study, we analysed only one selected polymorphism within the MMP-2 gene; therefore, our results do not exclude the involvement of other MMP-2 gene variations in AMD pathogenesis.

It is necessary to emphasize the limitations in our meta-analysis. First, only English-language articles were analysed, which may have limited the number of studies included in our meta-analysis. Second, not all the studies reported adjusted ORs, and adjustments for the level of confounders such as geographic distribution, type of AMD, ethnicity, age, and gender varied among them. Third, we did not specify our results according to AMD type due to the small sample size that could have reduced the statistical power. Finally, our meta-analysis was focused mainly on the Caucasian population as the Asian population provided only a relatively small sample size. Nevertheless, we have been able to overcome the statistical limitations of small sample size and homogeneous sample composition that is commonly encountered in allelic genetic association studies. Even with these limitations, this meta-analysis contributes significantly to our understanding of AMD because it is the first to clarify the risk of development associated with the rs243865 MMP-2 polymorphism. Multiple GWAS and meta-analysis studies for AMD have been published, but to our knowledge, none of them included in an analysis of the rs243865 MMP-2 polymorphism.

Conclusions {#sec017}
===========

In conclusion, our meta-analysis provides reliable evidence that rs243865 MMP-2 polymorphism is unlikely to be a risk factor for AMD development. Further investigations analysing the combined effect of genes and the environment may improve our current understanding of the association between the rs243865 or other MMP-2 polymorphisms and the risk of developing AMD, as well as the clinical and biological implications of other risk factors.
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